Feb 26, 2014
Ico Therapeutics: Near-Term Catalyst Presents Enormous Upside
We have decided to take a very detailed look at iCo Therapeutics and the company's Phase 2 drug for Diabetic Macular Edema , iCo-007, an anti-sense drug candidate in-licensed from ISIS Pharmaceuticals in 2005.
iCo Therapeutics Announces DTC Approval
DTC eligibility allows for iCo Therapeutics shares to be easily and economically transferred between brokerage accounts electronically.
iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering
The Offering is to be effected in each of the provinces of and elsewhere on a private placement basis.
Stockboard Media Inc.: Custom Stock Reports and Mobile Notifications on iCo Therapeutics
Richmond, British Columbia-- - Custom email stock reports and mobile news alert service for iCo Therapeutics are now available on Stockboard.com *Please note that changes on your web profile at www.stockboard.com will affect your mobile iPhone/iPad profile, and vice versa.